Chloe Ramirez
Lyme disease is a growing concern, with an estimated 476,000 people affected annually. While there is currently no approved human vaccine, several promising candidates are in development. The most advanced is VLA15, which has completed recruitment for Phase 3 trials. This vaccine candidate has demonstrated a strong immune response and a satisfactory safety profile. Other projects include an mRNA vaccine in preclinical development and a monoclonal antibody-based medication aiming for Phase 2-3 trials. The previous Lyme vaccine, LYMErix, was discontinued in 2002 due to low demand and adverse reactions. The development of a safe and effective vaccine is a priority, and researchers are optimistic about the market potential and public health impact.
| Characteristics | Values |
|---|---|
| Lyme disease vaccination for humans currently available | No |
| Previous Lyme disease vaccine | LYMErix® (or LYMErix) |
| Year of discontinuation of LYMErix® | 2002 |
| Reason for discontinuation of LYMErix® | Insufficient consumer demand |
| Current status of new Lyme disease vaccines | Clinical trials underway |
| Organizations developing vaccines | Valneva, Pfizer, University of Massachusetts Medical School's MassBiologics, Klempner and colleagues |
| Vaccine candidates | VLA15, monoclonal antibody |
| Vaccine type | Multivalent, protein subunit vaccine |
| Mechanism of action | Targets outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that causes Lyme disease |
| OspA | A surface protein expressed by the bacteria when present in a tick |
| Vaccine formulation | Alum-adjuvanted, administered intramuscularly |
| Number of doses | Three primary doses and one booster dose |
| Trial status | Phase 3 human trials |
| Trial participants | Approximately 6,000 participants, ages 5 and up |
| Trial sites | 50 sites in areas where Lyme disease is highly endemic across the U.S., Canada, and Europe |
| Trial duration | Initiated in August 2022 |
| Safety profile | No vaccine-related serious adverse events (SAEs) or safety concerns observed |
Explore related products
What You'll Learn
- The previous Lyme disease vaccine, LYMErix, was pulled from the market in 2002
- Clinical trials are underway for a new Lyme disease vaccine
- The VLA15 vaccine candidate is currently in Phase 3 trials
- An mRNA vaccine has shown promise in preclinical animal models
- A vaccine alternative, developed by MassBiologics, is undergoing human trials
The previous Lyme disease vaccine, LYMErix, was pulled from the market in 2002
There is currently no vaccine available for Lyme disease. The only vaccine that was previously marketed in the United States, LYMErix®, was discontinued by the manufacturer in 2002, citing insufficient consumer demand.
LYMErix® was the first human Lyme vaccine. Manufactured by SmithKline Beecham, it induced patients to produce antibodies that a tick would absorb from its victim’s blood, neutralizing the Borrelia burgdorferi bacterium that causes Lyme disease. However, within a year of licensure, reports of adverse reactions began to emerge. Musculoskeletal complaints, particularly arthritis, dominated the wide variety of claimed side-effects.
The vaccine also came with several limitations. Firstly, its efficacy was less than 80%, meaning that 20% of fully vaccinated individuals could still contract Lyme disease. Secondly, achieving full protection required three vaccine doses given at the time of the initial dose and 1 month and 12 months after the initial dose. Thirdly, the vaccine safety and efficacy database lacked tests in young children, a demographic at high risk of developing Lyme disease. The vaccine was also only effective against the predominant North American Borrelia strain, without necessarily protecting against international subspecies. Finally, uncertainty about the length of vaccine-induced immunity implied that recipients might need booster vaccine doses as often as every year.
Protection provided by the LYMErix® vaccine also decreases over time. Therefore, if you received this vaccine before 2002, you are no longer protected against Lyme disease.
Immunological Memory: What's the Truth?
You may want to see also
Explore related products
$19.03 $24.95
Clinical trials are underway for a new Lyme disease vaccine
Clinical trials are currently underway for a new Lyme disease vaccine, with two pharmaceutical companies at the forefront of these developments. Valneva and Pfizer have developed a Lyme disease vaccine candidate, VLA15, which is currently in Phase 3 human trials. This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick. Blocking OspA inhibits the bacterium's ability to leave the tick and infect humans.
VLA15 is designed to protect people against North American and European strains of the Lyme disease bacterium. The vaccine requires three doses, with the final primary series vaccination occurring just before the peak Lyme disease season for the region. Participants will then receive a booster dose 9-12 months after completing the primary immunization. The Phase 3 VALOR trial has enrolled 9,437 participants aged five and older, at sites in areas where Lyme disease is highly endemic across the U.S., Europe, and Canada. The trial includes volunteers with a cleared past infection with Borrelia burgdorferi, as well as Borrelia burgdorferi-naive volunteers.
The VLA15 candidate has demonstrated a strong immune response and a favorable safety profile across all dose and age groups in pre-clinical and clinical trials so far. No vaccine-related serious adverse events (SAEs) or safety concerns have been observed. A second Phase 3 trial is also fully recruited and aims to provide further evidence on the safety profile of VLA15 in the pediatric population.
The development of a Lyme disease vaccine is important as the disease is on the rise, with an estimated 476,000 people affected annually in the Northern Hemisphere, where it is the most common vector-borne illness. The growth of cases and public awareness have encouraged researchers that a market exists for prophylactics against Lyme. While there was a previous Lyme disease vaccine, LYMErix®, it was discontinued in 2002 due to insufficient consumer demand and reports of adverse reactions. Researchers are optimistic that their new products will overcome these challenges and provide an effective vaccine against Lyme disease.
Yellow Fever Vaccine: Lifetime Immunity?
You may want to see also
Explore related products
$20.41 $21.95
$19.19 $14.95
The VLA15 vaccine candidate is currently in Phase 3 trials
Lyme disease is a systemic infection caused by the Borrelia burgdorferi bacterium, transmitted to humans through the bite of an infected Ixodes tick. It is considered the most common vector-borne illness in the Northern Hemisphere, with approximately 476,000 people affected annually. The disease triggers a series of escalating symptoms, including a red rash, fatigue, fever, headache, and mild stiff neck. If left untreated, it can lead to severe complications affecting the joints, heart, and nervous system.
Currently, there is no approved human vaccine for Lyme disease. However, the VLA15 vaccine candidate, developed by Pfizer and Valneva, is the most advanced Lyme disease vaccine in clinical development. VLA15 is a multivalent protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria responsible for Lyme disease. OspA is a surface protein expressed by the bacteria when present in a tick, and inhibiting OspA prevents the bacterium from leaving the tick and infecting humans.
The second Phase 3 trial (C4601012) focuses on the pediatric population and aims to further evaluate the safety profile of VLA15 in younger individuals. This trial has also completed recruitment. Overall, the VLA15 candidate has demonstrated a robust immune response and a favorable safety profile across all dose and age groups in pre-clinical and clinical trials so far.
Vaccines Preventing STIs: What You Need to Know
You may want to see also
Explore related products
An mRNA vaccine has shown promise in preclinical animal models
Lyme disease is a bacterial infection transmitted to humans by the bite of an infected Ixodes tick. It is the most common vector-borne illness in the Northern Hemisphere, with approximately 476,000 people affected annually. The disease causes a range of symptoms, including a red rash, fatigue, fever, headache, and mild stiff neck. If left untreated, it can lead to severe complications in the joints, heart, and nervous system.
Currently, there is no approved human vaccine for Lyme disease. However, several vaccine candidates are in the clinical trials phase. One of the most promising candidates is VLA15, developed by Pfizer and Valneva. VLA15 is a multivalent protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. Blocking OspA inhibits the bacterium's ability to leave the tick and infect humans. VLA15 has demonstrated a strong immune response and a favourable safety profile in pre-clinical and clinical trials.
In addition to VLA15, researchers are also exploring alternative approaches to vaccination. MassBiologics, for example, is developing a human monoclonal antibody designed to be used as pre-exposure prophylaxis (PrEP) for Lyme disease. This approach offers a unique strategy by directly delivering a monoclonal antibody rather than stimulating the production of multiple antibodies in patients.
While these developments are encouraging, it is important to note that the history of Lyme disease vaccination has had its challenges. LYMErix, the first human Lyme vaccine, was introduced in the late 1990s but was discontinued in 2002 due to low consumer demand and reports of adverse reactions, including musculoskeletal complaints such as arthritis.
Amidst these challenges, an experimental mRNA vaccine has emerged as a promising candidate. This mRNA vaccine has demonstrated protection in preclinical animal models against infection from the bacteria that causes Lyme disease. The success of this vaccine in animal models suggests that it could be a potential solution for preventing Lyme disease in humans. The development of this mRNA vaccine leverages the latest advancements in mRNA vaccine technology, which has already proven successful in the creation of COVID-19 vaccines.
As clinical trials progress and research continues, the medical community remains hopeful that an effective and safe Lyme disease vaccine for humans will be approved in the near future. The increasing incidence of Lyme disease and its expanding geographic reach underscore the urgency of these efforts.
Influenza Vaccination Policy: What's the Truth?
You may want to see also
Explore related products
A vaccine alternative, developed by MassBiologics, is undergoing human trials
There is currently no vaccine for Lyme disease available for humans. The only vaccine previously marketed in the United States, LYMErix, was discontinued by the manufacturer in 2002 due to insufficient consumer demand and reports of adverse reactions. However, clinical trials of new vaccines are currently underway, with several promising candidates in development.
One of the most advanced vaccine candidates is VLA15, developed by Pfizer and Valneva. VLA15 is a multivalent protein subunit vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease. By blocking OspA, the vaccine inhibits the bacterium's ability to leave the tick and infect humans. VLA15 has demonstrated a strong immune response and a favourable safety profile in pre-clinical and clinical trials so far, with no vaccine-related serious adverse events reported. The Phase 3 VALOR trial of VLA15 has enrolled over 9,000 participants across the United States, Europe, and Canada, with participants receiving three doses of the vaccine or a placebo within the first year and a booster dose approximately one year later.
While the development of a traditional vaccine is ongoing, researchers at MassBiologics, affiliated with the University of Massachusetts Medical School, have developed a vaccine alternative that is undergoing human trials. This medication, referred to as a vaccine alternative because it directly delivers a monoclonal antibody rather than spurring the development of multiple antibodies in patients, is currently aiming for a phase 2-3 human trial. The approach would provide seasonal protection against Lyme disease and would likely consist of a single shot administered annually at the beginning of tick season.
The lack of an approved human vaccine for Lyme disease is not due to the complexity of developing one, as researchers have had success with clinical trials in the past. The previous vaccine, LYMErix, was pulled from the market due to factors that researchers today are confident can be overcome. The current projects are building on the basic strategy of those past vaccines, and the growing number of cases and public awareness have encouraged researchers that a market exists for prophylactics against Lyme disease.
Vaccine Coverage: Does Your Insurance Plan Measure Up?
You may want to see also
Frequently asked questions
No, there is currently no approved human vaccine for Lyme disease.
Yes, the first human Lyme vaccine, LYMErix, was available in the United States but was discontinued in 2002 due to insufficient consumer demand and reports of adverse reactions.
Yes, clinical trials of new vaccines are currently underway. Pfizer and Valneva have developed a Lyme disease vaccine candidate, VLA15, which is currently in Phase 3 human trials. This vaccine is designed to protect against North American and European strains of the Lyme disease bacterium.
One of the challenges is ensuring the vaccine's safety and efficacy. Previous vaccines had limitations, such as low efficacy, the need for multiple doses, and uncertainty about the length of immunity. Additionally, public perception and communication of risks and benefits are important considerations, as there may be concerns and hesitancy surrounding any new vaccine.
